Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

myRocky vs Näky

myRocky
Graded #487

Lower grade

vs+6.200000000000003
Näky
Graded #394

Higher grade

The verdict

Näky takes it — 57.6/100 to 51.4/100.

Näky grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Näky is a LegitScript-approved telehealth platform offering compounded semaglutide and tirzepatide alongside an uncommon oral semaglutide drops product and a separate GLP-1 microdose program, plus NAD+ and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNäky +11
34
45
Dose & formulationmyRocky +2
53
51
Clinical oversightNäky +12
64
76
Labs & monitoringEven
52
52
FulfillmentNäky +3
70
73
Contract termsNäky +14
41
55
myRocky · left barNäky · right bar

The numbers

MetricmyRockyNäky
WeighScore51.4/10057.6/100
GradeCC
Scorecard rank#487#394
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Näky

Graded #394 · C

Strengths

  • LegitScript Approved (verifiable for benaky.com)
  • Oral semaglutide drops as a distinct product line — uncommon among compounded GLP-1 brands
  • Separate GLP-1 microdose program offered
  • Adds NAD+ and Sermorelin for patients wanting a longevity stack
  • 3-minute online assessment with a same-day treatment plan

Where it loses points

  • Ongoing monthly pricing for compounded semaglutide and tirzepatide isn't shown until intake
  • Oral semaglutide drops and microdose program pricing not disclosed
  • Legal entity and state of incorporation not disclosed
  • Pharmacy partner not named — only a generic 'USA-based FDA-regulated' claim
  • States served not listed; pricing pages return 404s

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard